ISP Drug Shows Promising Results Rat Experiments to Treat Paralysis

by Dr. Trupti Shirole on December 5, 2014 at 9:58 AM
 ISP Drug Shows Promising Results Rat Experiments to Treat Paralysis

Laborartory studies in mice have shown that a drug called intracellular sigma peptide (ISP) has promising results in restoring functions like the ability to walk, to balance and urinate, lost due to paralyzing injury to the spinal cord.

Scientists are hoping that with further studies ISP could be used for therapy in humans. Jerry Silver, a professor of neurosciences at Case Western Reserve University in Cleveland, Ohio said, "We're very excited at the possibility that millions of people could, one day, regain movements lost during spinal cord injuries."


The research looked at ways of overcoming scarring when nerve fibers in the spinal cord are damaged and signals from the brain no longer reach muscles below the injury site. Nerve fibers try to cross the injury site and reconnect with other fibers, but become trapped at the scar site by sticky proteins called proteoglycans. ISP is designed to act on the receptor on the surface of the nerve cells which turns off a response to the proteoglycans that causes the blockage. ISP induced 'sprouting' of these fibers below the injury site.

During the experiment, 26 rats were given severe spinal cord injuries followed by daily injections of ISP for seven weeks. 21 of the 26 regained one or more of three functions - the ability to walk, to balance and to control when and how much they urinated. Some of them regained all three, others one or two, and five none of the functions.

The study is published in the journal Nature.

Source: Medindia
Font : A-A+



Recommended Readings

Latest Drug News

Can a Needle-Free Patch Transform Zika Protection?
Researchers create needle-free Zika vaccine patch, using HD-MAP tech, aiming to protect against fatal virus spread by mosquitoes.
Prolonging Market Exclusivity of Brand-name Insulin
Examining FDA and patent records, researchers found that insulin manufacturers prolong market exclusivity for brand-name products.
FDA Boosts Orphan Drug Designations for Myelofibrosis Treatments
The rise in FDA ODD awards indicates a collective endeavor to create new myelofibrosis medications devoid of mechanisms inducing anemia.
Anti-Rheumatic Drugs May Help Prevent Thyroid Disease
The most significant decrease in autoimmune thyroid disease risk was observed in rheumatoid arthritis patients receiving immunomodulatory drugs or 'biological DMARDs'.
Apotransferrin's Potential in Early Stroke Therapy Revealed
Human apotransferrin injected to mice models suffering from intracerebral hemorrhage was found to mitigate the serious effects of stroke.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

ISP Drug Shows Promising Results Rat Experiments to Treat Paralysis Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests